Navigation Links
Previously Disclosed Changes in Board Composition of NightHawk Radiology Holdings, Inc. Prompt Notice of Noncompliance from the Nasdaq Global Market
Date:3/12/2008

COEUR D'ALENE, Idaho, March 12 /PRNewswire-FirstCall/ -- As previously disclosed in its Form 8-K filed on February 28, 2008, NightHawk Radiology Holdings, Inc. (Nasdaq: NHWK) announced that Ernest G. Ludy has resigned from his position as a member of the company's Board of Directors for personal reasons. As a result of such departure, and as previously disclosed, the company does not comply with Nasdaq Marketplace Rule 4350(d)(2) -- which requires the company's Audit Committee to be comprised of at least three independent directors. After Mr. Ludy's resignation, the company's audit committee is now comprised of two independent directors.

On March 7, 2008, the Nasdaq Global Market delivered a letter to the company confirming the company's non-compliance with Nasdaq Marketplace Rule 4350(d)(2) and informing the company that it has until August 20, 2008 to regain compliance with this standard.

The company intends to timely comply with Nasdaq's request and to regain compliance as soon as practicable.

About NightHawk

NightHawk Radiology (Nasdaq: NHWK), headquartered in Coeur d'Alene, Idaho, is leading the transformation of the practice of radiology by providing high-quality, cost-effective solutions to radiology groups and hospitals throughout the United States. NightHawk provides the most complete suite of solutions, including professional services, business services, and its advanced, proprietary clinical workflow technology, all designed to increase efficiencies and improve the quality of pat
'/>"/>

SOURCE NightHawk Radiology Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Brain cells work differently than previously thought
2. Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation into Pricing, Sales and Marketing Practices
3. New transfusion rules restrict donations from previously pregnant women
4. Z Trim Holdings Reports Restatement of Previously Issued Financial Statements; Amends Bylaws
5. CDC Reports Prevalence of Worms Transmitted by Dogs and Cats to Humans is Higher Than Previously Understood
6. China Sky One Medical Completes Previously Announced Amendment to 2006 Form 10KSB
7. Symmetry Medical Provides Update of Previously Disclosed Accounting Review at Sheffield, UK Operating Unit
8. More functional DNA in genome than previously thought
9. The Ensign Group, Inc. Acquires Assets of Three Previously Leased Facilities
10. HealthSouth Announces Final Agreement on Previously Disclosed Settlement with Federal Government
11. China Sky One Medical Completes Previously Announced Amendments to Form 10QSB for the Second and Third Quarters of 2006
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 2Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 3Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 4Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 5Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 6Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 7Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 8Particle Sciences and IES Engineers Cooperate on High Potency Compound Handling Capabilities 2Particle Sciences and IES Engineers Cooperate on High Potency Compound Handling Capabilities 3Global Announces Contract To Acquire New Business 2Wound Management Technologies Inc Announced Today That It Has Reached an Agreement in Principal to Acquire BioPharma Management Technologies Inc 12648 1Wound Management Technologies Inc Announced Today That It Has Reached an Agreement in Principal to Acquire BioPharma Management Technologies Inc 12648 2Carbon Design Innovations Inc Introduces Carbon Nanotube Probe Technology for Atomic Force Microscopy CNT Probes Deliver New Level of AFM Imaging P 12645 1Carbon Design Innovations Inc Introduces Carbon Nanotube Probe Technology for Atomic Force Microscopy CNT Probes Deliver New Level of AFM Imaging P 12645 2Carbon Design Innovations Inc Introduces Carbon Nanotube Probe Technology for Atomic Force Microscopy CNT Probes Deliver New Level of AFM Imaging P 12645 3Finances Trigger American Reluctance to Spend More on Healthier Foods 49018 1Finances Trigger American Reluctance to Spend More on Healthier Foods 49018 2
Other Medicine Technology:Biomira Selects PX-866 as Clinical Development Candidate and,Presents Promising Preclinical Data at AACR 2Biomira Selects PX-866 as Clinical Development Candidate and,Presents Promising Preclinical Data at AACR 3Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 2Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 3Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 4Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 5Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 6Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 7Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 8Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 9